Cilnidipine

• 产品号: C1493
• CAS号: 132203-70-4
• 分子式: C27H28N2O7
• 分子量: 492.52042
• 纯 度: ≥98% (HPLC)
• 保 存: protect from light

产品别名

• 标题: Cilnidipine
• IUPAC标准名: 3-(2-methoxyethyl) 5-(3-phenylprop-2-en-1-yl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• IUPAC传统名: 3-(2-methoxyethyl) 5-(3-phenylprop-2-en-1-yl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• 别名: FRC 8653; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester

产品登记号

• MDL号: MFCD00865853
• PubChem SID: 24892414
• CAS号: 132203-70-4

产品性质

• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• GHS警示性声明: P280-P305 + P351 + P338
• 危险公开号: 41
• RTECS编号: US7975550
• 安全公开号: 26-39
• 保存条件: protect from light
• 德国WGK号: 3
• GHS警示词: Danger
• GHS危险声明: H318
• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• Empirical Formula (Hill Notation): C27H28N2O7
• 纯度: ≥98% (HPLC)
• 外观: light yellow powder
• 溶解度: H2O: ≤2 mg/mL
• 溶解度: DMSO: ≥20 mg/mL

产品详细信息

详细说明 (English)

Packaging
Protect from high temperatures.
Biochem/physiol Actions
Cilnidipine is a slow-acting Ca2+ channel blocker; antihypertensive; vasodilator; dual blocker of L-type voltage-gated Ca2+ channels in vascular smooth muscle and N-type Ca2+ channels in sympathetic nerve terminals that supply blood vessels. Cilnidipine may offer an advantage over nifedipine as the long term intake of the latter has been linked to increased risk of myocardial infarction and mortality in patients with coronary artery disease. Cilnidipine lowers blood pressure, but has less effect on sympathetic activity. Unlike nifedipine, cilnidipine does not inhibit PKC.

详细说明 (简体中文)

包装
Protect from high temperatures.
Biochem/physiol Actions
Cilnidipine is a slow-acting Ca2+ channel blocker; antihypertensive; vasodilator; dual blocker of L-type voltage-gated Ca2+ channels in vascular smooth muscle and N-type Ca2+ channels in sympathetic nerve terminals that supply blood vessels. Cilnidipine may offer an advantage over nifedipine as the long term intake of the latter has been linked to increased risk of myocardial infarction and mortality in patients with coronary artery disease. Cilnidipine lowers blood pressure, but has less effect on sympathetic activity. Unlike nifedipine, cilnidipine does not inhibit PKC.